A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours
Status:
Recruiting
Trial end date:
2021-12-10
Target enrollment:
Participant gender:
Summary
This is the first study to test SHR-1802 in humans. The primary purpose of this study is to
see if SHR-1802 is safe and tolerable for patients with locally advanced/unresectable or
metastatic malignancies that are refractory to available therapy or for which no standard
therapy is available.